CAMBRIDGE, Mass., Jan. 18 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated will announce its fourth quarter and full year 2005 financial results on Tuesday, February 7, 2006 after the financial markets close. The Company will host a conference call at 4:30 p.m. EST. The conference call also will be webcast.
The live webcast will be available to all interested parties through Vertex’s website, http://www.vrtx.com, and will be archived on the Company’s website until February 21, 2006. To access the webcast, go to the investor center and select ‘conference calls.’ To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.
About Vertex
Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company’s strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex’s product pipeline is principally focused on viral diseases, inflammation, autoimmune diseases and cancer. Vertex co-promotes the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.
Lexiva is a registered trademark of the GlaxoSmithKline group of companies.
Vertex’s press releases are available at http://www.vrtx.com. Vertex Contact: Lora Pike, Manager, Investor Relations, (617)-444-6755
Vertex Pharmaceuticals Incorporated
CONTACT: Lora Pike, Manager of Investor Relations at VertexPharmaceuticals Incorporated, +1-617-444-6755
Web site: http://www.vrtx.com/
Company News On-Call: http://www.prnewswire.com/comp/938395.html/
